Table 3. Association between the presence/absence of activating KIR genes and risk for CD in the Montreal pediatric cohort.
| Gene | Patients | Controls | OR (95% CI) | P-values |
|---|---|---|---|---|
| N (%) | N (%) | |||
| 2DS1 | ||||
| + | 127 (65.8) | 102 (41.6) | 2.70 (1.8–4.0) | 6.7 x 10−7 |
| - | 66 (34.2) | 143 (58.4) | ||
| 2DS2 | ||||
| + | 123 (63.7) | 138 (56.3) | 1.36 (0.93–2.0) | 0.12 |
| - | 70 (36.3) | 107 (43.7) | ||
| 2DS3 | ||||
| + | 111 (57.5) | 83 (33.9) | 2.64 (1.79-.3.90) | 1.01 x 10−6 |
| - | 82 (42.5) | 162 (66.1) | ||
| 2DS4 | ||||
| + | 137 (71.0) | 139 (56.7) | 1.87 (1.25–2.78) | 0.002 |
| -* | 56 (29.0) | 106 (43.3) | ||
| 2DS5 | ||||
| + | 140 (72.5) | 104 (42.4) | 3.58 (2.39–5.37) | 8.0 x 10−10 |
| - | 53 (27.5) | 141 (57.6) | ||
| 3DS1 | ||||
| + | 126 (65.3) | 101 (41.2) | 2.68 (1.81–3.96) | 7.4 x 10−7 |
| - | 67 (34.7) | 144 (58.8) |
* indicates the presence of the 22 bp deleted forms and/or absence of the gene